The surface of a cell, which is covered with tens to hundreds of thousands of molecules that assist immune cells to distinguish friend from foe, can reveal a cell's secrets. Some of those projecting molecules are antigens that cause the immune system to attack, but identifying those antigens in the molecular forest can be challenging because they differ between individuals.

The findings of the research were published in the journal Nature Methods. A team of Stanford scientists led by Polly Fordyce, an Institute Scholar at Sarafan ChEM-H, has developed a new method to faster and more accurately predict which antigens will lead to a strong immune response. Their approach could help scientists develop more effective cancer immunotherapies.

T cells, a class of immune cells, crawl along and squish past other cells as they patrol the body, using T cell receptors to molecularly read peptides or short pieces of proteins - which are cradled within larger proteins called major histocompatibility complexes (pMHCs) that project from cell surfaces.

Healthy host cells display an array of pMHCs that do not trigger an immune response, but once T cells recognise disease-indicating peptides, they become activated to find and kill cells bearing these foreign signatures.

Understanding how T cells sensitively distinguish these antigenic peptides from host peptides to avoid mistakenly killing host cells has long been a mystery. "A T cell can detect a single antigenic peptide amongst a sea of 10,000 or 100,000 non-antigenic peptides being displayed on cell surfaces," said Fordyce, assistant professor of bioengineering and of genetics.

The key to selectivity is in the T cell crawl. T cells' sliding puts stress on the bonds between receptors and peptides, and in most cases, that extra stress is enough to break that bond. But sometimes, it has the opposite effect. Chris Garcia, co-author of the study and professor of molecular and cellular physiology and of structural biology, and others had already shown that the most antigenic peptides are those whose interactions with T cell receptors grow stronger in response to sliding.

"It's kind of like a Chinese finger trap," said Fordyce. "When you pull a bit at the receptor-antigen interaction, the binding actually lasts longer."

Cellular mimicry

Identifying the best antigen-receptor pairs requires simultaneously applying that sliding, or shear, the force between a peptide and a T cell and measuring T cell activation, ideally thousands of times to get repeatable data for many possible peptide/T cell receptor pairs. But existing methods are time-intensive and can result in measuring only one peptide with hundreds of T cells in a day.

The study's first author, postdoctoral scholar Yinnian Feng, developed a trick that allows the team to measure 20 unique peptides interacting with thousands of T cells in less than five hours.

To make a simplified system that mimics cells with dangling peptides, they constructed small spherical beads from a material that expands upon heating and attached a few molecules of a given peptide-studded pMHC to their surfaces. After depositing a T cell atop each bead and waiting long enough for receptors to bind to the peptides, they then very slightly heated the bead.

The bead's expansion increases the distance between tether points, and the corresponding stretching of the T cell mimics the force it would experience sliding along cells in the body. After exerting that force, the team then measured how active the T cells were.

They could do hundreds of individual experiments in parallel by using beads that are each labelled with a unique colour, making it possible to track multiple different pMHCs. They took two sets of pictures tiling across each slide after each run: one set that tells them which pMHC a given bead is displaying and another that tells them how active each T cell atop that bead is. Cross-referencing those images tells them which antigens led to the strongest T cell responses.

In this demonstration of their platform, the team showed, with 21 unique peptides, that their results confirmed known activating and non-activating peptides for one T cell receptor and uncovered a previously unknown antigen that induced a strong T cell response.

Working with the Garcia lab, they have also already begun to address a challenge in immunotherapy: the T cell receptors that form the highest affinity interactions with antigens in the lab are often also activated by non-antigenic peptides in the body, a dangerous side effect that leads to the killing of healthy cells.

Using their technology, the team characterised T cell receptors engineered to specifically recognise tumour antigens without off-target reactivity. In future work, they plan to build libraries of over 1,000 peptides to uncover novel antigens. They hope that this approach, which is quick and requires few cells, or an optimised form of it could one day be used to improve personalised immunotherapies.

"This platform can help improve efforts to engineer T cells that specifically target cancer cells, as well as determine which antigens are capable of potently activating a patient's own T cells to more effectively target cancer cells," said Fordyce.